Emeryville, United States
Gritstone bio, founded in 2015 and headquartered in the United States, positions itself as a pioneering force within the Biotechnology, Health Care, and Health and Wellness industries. With its slogan, "A lean biotech company aiming to develop revolutionary immune-based treatment for various cancers," the company emphasizes its innovative approach in immuno-oncology and infectious disease treatment.
Backed by a team of distinguished scientific founders and advisors, Gritstone bio aims to redefine cancer and infectious disease therapies by harnessing the immune system’s ability to target diseased cells. Initially focusing on tumor-specific neoantigens, the company has expanded to include viral antigens, potentially broadening its therapeutic horizon significantly.
Following a recent $32.50M Post-IPO Equity investment in April 2024, Gritstone bio is poised to advance its next-generation vaccine development, offering a promising avenue for investors seeking to contribute to transformative healthcare solutions.
